Guangzhou-based Lupeng Pharmaceuticals, a clinical-stage firm that focuses on drug discovery and developing novel therapies for cancer, has snapped up $35 million in the second tranche of its pre-Series B round.
The round was led by Hangzhou-headquartered Kaitai Capital and Singapore state investor Temasek, Lupeng announced via its WeChat account.
